Lynparza (olaparib tablets – AstraZeneca) — Cigna
Ovarian, Fallopian Tube, or Primary Peritoneal Cancer – Maintenance, Combination Therapy
Initial criteria
- Patient is age ≥ 18 years
- Medication is used in combination with bevacizumab
- Patient has homologous recombination deficiency (HRD)-positive disease confirmed by an approved test
- Patient is in complete or partial response to first-line platinum-based chemotherapy regimen
Approval duration
1 year